{"commentary":{"count":460,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":167,"youtube":163,"podcast":126,"x_video":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04494425\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DB-06","nct_id":"NCT04494425","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=db-06-nct04494425. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"DB-06","arms":[{"description":"Trastuzumab deruxtecan (T-DXd; DS-8201a) arm","label":"Trastuzumab deruxtecan","type":"EXPERIMENTAL"},{"description":"Investigator's choice standard of care chemotherapy (capecitabine, paclitaxel, nab-paclitaxel) arm","label":"Standard of Care","type":"ACTIVE_COMPARATOR"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2026-06-19","type":"ESTIMATED"},"conditions":["Advanced or Metastatic Breast Cancer"],"enrollment":{"count":866,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Trastuzumab deruxtecan","type":"DRUG"},{"name":"Capecitabine","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Nab-Paclitaxel","type":"DRUG"}],"last_update":"2026-03-04","lead_sponsor":"AstraZeneca","official_title":"A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-03-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population","timeFrame":"Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)"}],"references":[{"citation":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im SA, Levy C, Jacot W, Begbie N, Ke J, Patel G, Curigliano G; DESTINY-Breast06 Trial Investigators. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med. 2024 Dec 5;391(22):2110-2122. doi: 10.1056/NEJMoa2407086. Epub 2024 Sep 15.","pmid":"39282896","type":"DERIVED"},{"citation":"Tarantino P, Tolaney SM, Curigliano G. Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment. Ann Oncol. 2023 Oct;34(10):949-950. doi: 10.1016/j.annonc.2023.07.003. Epub 2023 Jul 26. No abstract available.","pmid":"37499870","type":"DERIVED"}],"start_date":{"date":"2020-07-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04494425"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/db-06-nct04494425"}